Trust Co. of Vermont Reduces Position in The Clorox Company (NYSE:CLX)

Trust Co. of Vermont reduced its stake in shares of The Clorox Company (NYSE:CLX) by 9.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,634 shares of the company’s stock after selling 2,130 shares during the period. Trust Co. of Vermont’s holdings in Clorox were worth $3,085,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CLX. Choreo LLC lifted its position in Clorox by 12.8% during the 4th quarter. Choreo LLC now owns 5,741 shares of the company’s stock worth $819,000 after acquiring an additional 652 shares during the period. abrdn plc lifted its holdings in shares of Clorox by 20.1% during the fourth quarter. abrdn plc now owns 198,250 shares of the company’s stock worth $28,268,000 after purchasing an additional 33,135 shares during the period. Savoir Faire Capital Management L.P. boosted its position in Clorox by 61.8% in the fourth quarter. Savoir Faire Capital Management L.P. now owns 65,192 shares of the company’s stock valued at $9,296,000 after buying an additional 24,897 shares during the last quarter. International Assets Investment Management LLC increased its holdings in Clorox by 17,658.5% in the 4th quarter. International Assets Investment Management LLC now owns 484,453 shares of the company’s stock worth $69,078,000 after buying an additional 481,725 shares during the period. Finally, Victory Capital Management Inc. raised its position in Clorox by 3.9% during the 4th quarter. Victory Capital Management Inc. now owns 172,526 shares of the company’s stock worth $24,600,000 after buying an additional 6,510 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on CLX shares. The Goldman Sachs Group started coverage on shares of Clorox in a research note on Friday, March 1st. They issued a “sell” rating and a $140.00 price objective on the stock. Barclays cut their price target on Clorox from $136.00 to $132.00 and set an “underweight” rating on the stock in a research report on Thursday, May 2nd. JPMorgan Chase & Co. decreased their price objective on Clorox from $159.00 to $158.00 and set a “neutral” rating for the company in a report on Wednesday, May 1st. Citigroup dropped their target price on Clorox from $155.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 1st. Finally, Jefferies Financial Group raised Clorox from an “underperform” rating to a “hold” rating and set a $145.00 price target for the company in a report on Tuesday, March 26th. Four equities research analysts have rated the stock with a sell rating and fourteen have issued a hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $146.43.

Clorox Price Performance

Shares of NYSE CLX opened at $137.96 on Tuesday. The stock has a market capitalization of $17.13 billion, a price-to-earnings ratio of 71.48, a price-to-earnings-growth ratio of 2.17 and a beta of 0.39. The Clorox Company has a 52 week low of $114.68 and a 52 week high of $169.14. The firm has a 50-day simple moving average of $138.13 and a 200-day simple moving average of $144.18. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 9.73.

Clorox (NYSE:CLX) last released its earnings results on Tuesday, April 30th. The company reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.38. The business had revenue of $1.81 billion for the quarter, compared to analyst estimates of $1.87 billion. Clorox had a net margin of 3.33% and a return on equity of 302.49%. The business’s revenue was down 5.3% on a year-over-year basis. During the same period last year, the company posted $1.51 EPS. On average, equities analysts predict that The Clorox Company will post 5.84 earnings per share for the current fiscal year.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.